BioSpace News Archive

argenx (Euronext & Nasdaq: ARGX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for VYVGART® (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive1.

BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze® (glucarpidase) for treating adult patients in the United States who experience delayed methotrexate elimination due to impaired renal function.

EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced publication of results in the well-respected, international journal, Frontiers in Immunology, from a small 12 patient, 12-week, open label Phase 1 clinical trial called PRIMETIME (NCT02518958).

lino Biotech announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”) today announces it is working on the development of its lead candidate, the AD04™ compound for the treatment of early Alzheimer’s disease (AD).

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that two abstracts related to the company’s novel molecular glue SP-3164 have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting.

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.

IMUNON, Inc.(NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, FL and virtually.

Adela, Inc. announced today that it will present data demonstrating the ability of its genome-wide methylome enrichment platform to detect multiple types of cancer at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.